Orforglipron, Research Reference
Orforglipron (development code LY3502970) is a non-peptide small molecule GLP-1 receptor agonist developed by Eli Lilly and Company. It is the first orally administered non-peptide GLP-1 receptor agonist to reach Phase 3 clinical development, and represents a structurally distinct approach to GLP-1 receptor agonism compared to the peptide analogues (semaglutide, tirzepatide, liraglutide, retatrutide) that currently dominate the class.
Important structural note: Orforglipron is not a peptide. It is a small molecule that achieves GLP-1 receptor activation through a chemically synthesised non-peptide scaffold. It is discussed on this site alongside peptide GLP-1 agonists because it targets the same receptor and is relevant to anyone researching the GLP-1 agonist class, not because it shares the peptide structure of the other compounds on this site.
Quick Reference
| Parameter | Reported Value |
|---|---|
| Type | Non-peptide small molecule GLP-1 receptor agonist |
| Developer | Eli Lilly and Company |
| Development code | LY3502970 |
| Route | Oral (once weekly) |
| Half-life | ~5 days |
| Phase 3 trial doses | 12 mg, 24 mg, 36 mg, 45 mg once weekly |
| Weight loss reported (Phase 3, 36 wks) | ~15–16% at 36–45 mg |
| Development status | Phase 3 (ATTAIN programme); not approved |
| Administration requirement | Oral; no fasting requirement (unlike oral semaglutide) |
Overview
All approved and investigational GLP-1 receptor agonists before orforglipron have been peptide-based analogues of the endogenous GLP-1 hormone, requiring injectable administration because peptide structures are degraded by gastrointestinal proteases before reaching systemic circulation in meaningful concentrations. Orforglipron breaks from this pattern by using a non-peptide small molecule structure that can be absorbed orally without the limitations inherent to peptide delivery.
Research has investigated orforglipron as part of Eli Lilly’s ATTAIN clinical programme for:
- Weight management in obesity: Phase 3 trial data have reported approximately 15–16% body weight reduction at 36 weeks at doses of 36–45 mg once weekly, positioning orforglipron in a similar efficacy range to once-weekly subcutaneous semaglutide.
- Type 2 diabetes management: Phase 3 trials have investigated orforglipron for glycaemic control, with Phase 2 data reporting meaningful HbA1c reductions and weight loss in participants with type 2 diabetes.
- Oral GLP-1 agonism as an alternative to injection: The primary research and clinical interest in orforglipron centres on its oral route of administration, which research has proposed may improve adherence and accessibility compared to injectable analogues.
Orforglipron is not approved by the FDA or EMA as of this reference. It is in Phase 3 development and is not commercially available.
Mechanism
Orforglipron achieves GLP-1 receptor agonism through a non-peptide chemical scaffold that engages the same GLP-1 receptor as semaglutide and other GLP-1 peptide agonists. The downstream pharmacological consequences of receptor activation are the same:
- Glucose-dependent insulin secretion: GLP-1 receptor activation on pancreatic beta cells potentiates insulin release in response to elevated blood glucose, with the effect diminishing at euglycaemia. This glucose-dependence substantially limits hypoglycaemia risk compared to insulin secretagogues that operate independently of glucose levels.
- Glucagon suppression: GLP-1 receptor agonism on pancreatic alpha cells suppresses glucagon secretion, reducing hepatic glucose output in the postprandial period.
- Gastric emptying delay: GLP-1 receptor activation slows gastric emptying, blunting postprandial glucose excursions and contributing to satiety through prolonged gastric distension signalling.
- Hypothalamic appetite suppression: GLP-1 receptors in the hypothalamus and brainstem mediate appetite-suppressing effects, reducing caloric intake. This central mechanism is a primary driver of the weight loss observed with GLP-1 receptor agonists as a class.
Why oral delivery is feasible for orforglipron: The reason peptide GLP-1 agonists require injection is that peptide structures are susceptible to protease cleavage in the gastrointestinal tract. Orforglipron’s non-peptide scaffold is not susceptible to this degradation, allowing conventional oral absorption across the intestinal epithelium. Additionally, unlike oral semaglutide (Rybelsus), which uses an absorption enhancer (SNAC) and requires fasting administration, orforglipron does not require food-timing restrictions, making it a true once-weekly oral tablet.
Trial Protocol Data
The following doses were used in published Phase 2 and Phase 3 clinical trials. This information reflects the research context; there is no established community protocol for orforglipron as it is not a compounded or commercially available research compound.
Phase 3 ATTAIN Programme Doses
Orforglipron was evaluated in Phase 3 trials at doses of 12 mg, 24 mg, 36 mg, and 45 mg once weekly, administered orally.
- Dose escalation: Published Phase 2 trial designs used dose escalation phases (similar in concept to the titration schedules used with semaglutide and tirzepatide) to improve gastrointestinal tolerability during initial weeks of treatment
- Administration: Once-weekly oral tablet; no food restrictions required
- Duration in Phase 3: Trials have evaluated orforglipron at 36 weeks and longer
The ATTAIN-1 trial (obesity) reported approximately 15–16% weight loss at 36 weeks at the 36–45 mg dose ranges, with GI side effects (nausea, diarrhoea) consistent in profile with other GLP-1 receptor agonists.
Reported Effects
The following effects are drawn from published clinical trial data. This list reflects the research landscape, not confirmed outcomes in general populations.
Weight Reduction
Phase 3 data from the ATTAIN programme reported approximately 15–16% body weight loss at 36 weeks at the 36–45 mg doses in participants with obesity, representing clinically meaningful weight reduction. Lower doses (12–24 mg) produced lesser but meaningful weight reduction. The magnitude of weight loss observed with orforglipron is broadly comparable to once-weekly subcutaneous semaglutide (Wegovy) in the STEP trials, and somewhat lower than the highest-dose tirzepatide results in SURMOUNT.
Glycaemic Control
Phase 2 trial data in participants with type 2 diabetes reported meaningful HbA1c reductions alongside weight loss. Phase 3 type 2 diabetes trials are ongoing as of this reference. The glucose-dependent mechanism of GLP-1 receptor agonism limits hypoglycaemia risk, consistent with other compounds in the class.
Cardiovascular and Metabolic Parameters
Trial data have reported reductions in blood pressure and favourable changes in lipid parameters consistent with weight loss. Dedicated cardiovascular outcomes trial data for orforglipron are not yet available; the CVOT programmes that established cardiovascular mortality benefits for semaglutide (LEADER/SUSTAIN-6) and liraglutide took years of long-term follow-up to complete, and equivalent data for orforglipron have not been published as of this reference.
Reported Side Effects
Reported side effects from clinical trial data include the following. The side effect profile for orforglipron appears consistent with the GLP-1 receptor agonist class.
| Side Effect | Frequency Reported |
|---|---|
| Nausea | Common, particularly during dose escalation |
| Vomiting | Common, particularly during dose escalation |
| Diarrhoea | Common |
| Decreased appetite | Common (pharmacological, typically desired in weight management context) |
| Constipation | Occasionally reported |
| Fatigue | Occasionally reported |
The GI side effects observed in orforglipron trials are qualitatively similar to those observed with semaglutide and tirzepatide: most pronounced during initial dose escalation, generally attenuating after the stabilisation period. No novel safety signals significantly differentiated orforglipron from the established GLP-1 agonist class in published Phase 2 and interim Phase 3 data. Orforglipron trials have not reported musculoskeletal adverse events at the frequency observed in some analyses of semaglutide-associated muscle mass changes, though this requires longer-term data to characterise.
Orforglipron vs Injectable GLP-1 Agonists
| Feature | Orforglipron | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|---|
| Type | Non-peptide small molecule | Peptide analogue | Peptide analogue |
| Route | Oral (once weekly) | Subcutaneous (once weekly) | Subcutaneous (once weekly) |
| Half-life | ~5 days | ~1 week | ~5 days |
| Receptor targets | GLP-1R | GLP-1R | GLP-1R + GIPR |
| Phase 3 weight loss | ~15–16% (36 wks) | ~14–15% (68 wks) | ~20–22% (72 wks) |
| Approval status | Phase 3, not approved | Approved (obesity, T2D) | Approved (obesity, T2D) |
| Key advantage | No injection; no fasting requirement | Extensive outcomes data | Higher weight loss ceiling |
Orforglipron’s primary differentiator is its oral route without food restrictions, which may represent a meaningful adherence and accessibility advantage. Its weight loss efficacy appears comparable to semaglutide but lower than tirzepatide at equivalent duration. Tirzepatide’s dual GLP-1/GIP agonism is proposed as the mechanism for its superior weight loss magnitude.
Frequently Asked Questions
Is Orforglipron a peptide? No. Orforglipron is not a peptide. It is a non-peptide small molecule GLP-1 receptor agonist, meaning it achieves GLP-1 receptor binding and activation through a chemically synthesised small molecule structure rather than a peptide sequence. This is the key structural distinction from semaglutide, tirzepatide, liraglutide, and other injectable GLP-1 agonists, which are all peptide analogues of the endogenous GLP-1 hormone. Despite this structural difference, orforglipron activates the same GLP-1 receptor and produces the same downstream pharmacological effects. Orforglipron is discussed alongside peptide GLP-1 agonists because it targets the same receptor and is relevant to anyone researching this class, not because it shares their peptide structure.
Why is oral GLP-1 receptor agonism significant, and how does orforglipron achieve it? Peptide GLP-1 analogues cannot be administered orally because peptides are degraded by gastrointestinal proteases before they can be absorbed. The oral semaglutide formulation (Rybelsus) partially overcomes this through the SNAC absorption enhancer, but requires strict fasting administration and achieves comparatively lower bioavailability. Orforglipron, as a non-peptide small molecule, is not susceptible to protease degradation. Small molecules can typically be absorbed across the intestinal epithelium directly, without absorption enhancers or fasting requirements. This enables orforglipron to be taken as a conventional once-weekly oral tablet without food-timing restrictions.
How do orforglipron’s trial results compare to semaglutide and tirzepatide? Phase 3 data for orforglipron have reported approximately 15–16% weight loss at 36 weeks at higher dose ranges (36–45 mg), broadly comparable to semaglutide 2.4 mg (Wegovy) in the STEP programme, where approximately 14–15% was reported at 68 weeks. Tirzepatide (Zepbound) has shown approximately 20–22% in SURMOUNT trials at its highest doses. Orforglipron positions as comparably effective to semaglutide with the oral route as its primary advantage. Head-to-head trials versus semaglutide or tirzepatide have not been completed.
What is the current development status of Orforglipron? As of mid-2026, orforglipron is in Phase 3 clinical development by Eli Lilly under the ATTAIN programme. It is not yet approved by the FDA or EMA and is not commercially available. It is not a compounded or registered research chemical in the same category as peptides such as semaglutide. The information on this page is based on published Phase 2 and interim Phase 3 trial data and is provided in a research and information context only.
Related Pages
Goals: Fat Loss & Body Composition · Metabolic Health
Class: GLP-1 / GIP / Glucagon Agonists
Comparisons: Orforglipron vs Semaglutide
Also see: Semaglutide · Tirzepatide · Retatrutide · CagriSema
References & Further Reading
- Wharton S, et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine, 389(10), 877–888. PubMed
- Rosenstock J, et al. (2023). Efficacy and safety of a novel non-peptide GLP-1 receptor agonist orforglipron in patients with type 2 diabetes. Lancet, 402(10400), 472–483. PubMed
- Eli Lilly ATTAIN Phase 3 programme. ClinicalTrials.gov identifiers NCT05971992 and related trials.